Gamida Cell Ltd. logo
Gamida Cell Ltd. GMDA

Gamida Cell Ltd. Financial Statements 2011-2026 | GMDA

Annual Financial Statements Gamida Cell Ltd.

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

- 353 M 152 M 359 M - - - - - - -

Shares

- 43.8 M 33.7 M 24.9 M - - - - - - -

Historical Prices

2.54 8.39 4.3 9.94 - - - - - - -

Net Income

- -72.7 M -34.4 M -52.9 M -19 M -22.7 M - - - - -

Operating Income

- -62.3 M -48.2 M -33.6 M -19.5 M -23.7 M - - - - -

EBITDA

- -62.7 M -46.1 M -33.4 M -19.3 M -23.6 M - - - - -

Operating Expenses

- - 48.2 M 33.6 M 19.5 M 23.7 M - - - - -

General and Administrative Expenses

- 19.8 M 11.2 M 11.6 M 4.47 M 4.61 M - - - - -

All numbers in USD currency

Quarterly Income Statement Gamida Cell Ltd.

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

- - - - - - - - - - - - - - 26 M - - - 690 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

- - - - - -19.6 M -21.3 M - - -14.8 M -15.1 M - - - 5.96 M - - - -13.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

- - - - - -23.1 M -22.5 M - - -15.1 M -12.8 M - - - -10.8 M - - - -9.89 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- - - - - -23.1 M -22.5 M - - -15.1 M -12.8 M - - - -10.8 M - - - -9.89 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

- - - - - 4.77 M 3.82 M - - 2.69 M 2.5 M - - - 2.45 M - - - 2.92 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Gamida Cell Ltd. GMDA
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Gamida Cell Ltd. plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.36 -2.52 % $ 362 M britainBritain
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
DBV Technologies S.A. DBV Technologies S.A.
DBVT
$ 20.25 -0.54 % $ 2.83 B franceFrance
Dyadic International Dyadic International
DYAI
$ 0.87 0.59 % $ 31.5 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.78 4.83 % $ 9.09 B australiaAustralia
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.6 -2.26 % $ 16.3 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Fate Therapeutics Fate Therapeutics
FATE
$ 1.14 -4.2 % $ 135 M usaUSA
Forte Biosciences Forte Biosciences
FBRX
$ 26.44 - $ 342 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Fennec Pharmaceuticals Fennec Pharmaceuticals
FENC
$ 6.16 -4.05 % $ 176 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Amicus Therapeutics Amicus Therapeutics
FOLD
$ 14.46 0.03 % $ 4.46 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Fulcrum Therapeutics Fulcrum Therapeutics
FULC
$ 7.57 -3.32 % $ 480 K usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Galectin Therapeutics Galectin Therapeutics
GALT
$ 2.28 -11.13 % $ 146 M usaUSA
Gilead Sciences Gilead Sciences
GILD
$ 138.34 -1.28 % $ 172 B usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
$ 0.54 4.28 % $ 503 K israelIsrael
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Genmab A/S Genmab A/S
GMAB
$ 27.14 -2.2 % $ 17 B danmarkDanmark
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
BioNTech SE BioNTech SE
BNTX
$ 88.2 -3.37 % $ 27.2 B germanyGermany
Gossamer Bio Gossamer Bio
GOSS
$ 0.32 -7.11 % $ 73.1 M usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.62 -3.29 % $ 190 M usaUSA
Grifols, S.A. Grifols, S.A.
GRFS
$ 7.98 -3.04 % $ 6.83 B spainSpain
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
$ 3.5 -1.13 % $ 236 B britainBritain
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
GT Biopharma GT Biopharma
GTBP
$ 0.41 -8.56 % $ 2.26 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 316.69 -4.13 % $ 41.5 B usaUSA
Halozyme Therapeutics Halozyme Therapeutics
HALO
$ 63.72 1.01 % $ 7.64 B usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Harmony Biosciences Holdings Harmony Biosciences Holdings
HRMY
$ 27.53 -0.67 % $ 1.58 B usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 4.53 1.0 % $ 726 M britainBritain
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA